ATON - Hybrigenics' patent on its fifth chemical family of inhibitors of Ubiquitin-Specific Protease (USP) has been granted in Europe, Japan and the United States
Hybrigenics' estate of granted patents is the widest of the published intellectual property in the field of USP inhibitors
Hybrigenics had already patented a chemical series of specific irreversible "suicide" inhibitors of USP7 (see Hybrigenics' press release of September 04, 2014) after three other series of USP8 inhibitors or pan-USPs inhibitors. In total, Hybrigenics' intellectual property on USP inhibitors amounts to 72 granted and 22 pending patents protecting five chemical families and covers more than thirty countries.
Proteases play a key role in a number of pathological processes and several protease inhibitors are widely used as successful drugs (for example, ACE-inhibitors for hypertension, thrombin inhibitors as anticoagulants, HIV-1 protease inhibitors in AIDS and HCV protease inhibitors for hepatitis C). Ubiquitin-Specific Proteases belong to the group of de-ubiquitinating enzymes responsible for the recycling of proteins. Inhibiting the recycling of oncoproteins (proteins involved in the development of cancer), of neuronal proteins or of viral proteins will force their degradation, and this could slow-down the progression of certain cancers, neurodegenerative diseases or viral infections, respectively. Hybrigenics is focusing on the anti-cancer potential of USP inhibitors.
"Hybrigenics' pioneering research on USP inhibitors has yielded the widest estate of granted patents of this promising field. Hybrigenics continues to capitalize on these assets to advance its research projects in oncology,"said Remi Delansorne, Hybrigenics' CEO.
About HybrigenicsHybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases.
Hybrigenics' development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Inecalcitol has been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. Two clinical Phase II studies of inecalcitol are currently ongoing in chronic myeloid leukemia and acute myeloid leukemia. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold- standard chemotherapeutic treatment for this indication.
Hybrigenics' research program is exploring the role of enzymes called Ubiquitin-Specific Proteases (USP) in the balance between degradation and recycling of proteins called onco-proteins due to their involvement in various cancers. Hybrigenics is evaluating the interest of inhibitors of USP as anti-cancer drug candidates. Hybrigenics has collaborated with Servier on one particular USP in oncology. In this R&D program, two steps have been reached and additional milestones may be achieved until registration of a potential drug. Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.
*** HYBRIGENICS is listed on the Alternext market of Euronext Paris ISIN: FR0004153930 Ticker: ALHYGHybrigenics Rémi Delansorne CEO Tel.: +33 (0)1 58 10 38 00 investors@hybrigenics.com | NewCap Financial communication Julien Perez / Pierre Laurent Tel.: +33 (0)1 44 71 94 94 hybrigenics@newcap.eu |
Hybrigenics SA published this content on 26 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 January 2017 23:44:09 UTC.
Public permalinkhttp://www.publicnow.com/view/1821126241B2B46A2C11DA58FC136B836175AE3F
